Neurokinin 3 receptor agonist senktide stimulates GnRH release in isolated hypogonadotropic hypogonadism mice
- FASEB J. 2025 Mar 31;39(6):e70498. doi: 10.1096/fj.202403365R.
- 1. Department of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, China.
- 2. School of Medicine, The University of Missouri, Columbia, Missouri, USA.
Isolated hypogonadotropic hypogonadism (IHH) is caused by defective gonadotropin-releasing hormone (GnRH) secretion or action, resulting in absent or incomplete pubertal development and infertility. However, the pathogenesis mechanism of IHH is not fully understood. This study utilized PROK2/PROKR2 knockdown mice and GT1-7 cells to investigate the effects and potential mechanismsof the NK3R Agonist senktide on GnRH deficiency and related syndromes. In this investigation, PROK2/PROKR2 knockdown resulted in a deficiency of GnRH neurons, reduced levels of LSH, FSH, and E2, and the inhibition of the MAPK/ERK and PI3K/Akt pathways in mice. However, this effect was reversed by senktide. Furthermore, the inhibition of MAPK/ERK or PI3K/Akt signaling pathways counteracted the remission of the GnRH insufficiency and associated syndrome by senktide in mice with PROK2/PROKR2 knockdown. In summary, NK3R Agonist senktide alleviated the GnRH insufficiency and related syndromes caused by PROK2/PROKR2 knockdown via the MAPK/ERK pathway and the PI3K/Akt pathway.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Neurokinin Receptor